| Drug / Therapy | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo |
| Indication | — |
| Decision Type | Phase 1 |
| Trial Phase | Phase 1 |
| ClinicalTrials.gov | NCT05950464 |
Cara Therapeutics (CARA) operates in the Nephrology sector. The current BTS Score is 66 (Grade: B).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Phase 1 date for Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo by Cara Therapeutics (CARA) is scheduled for April 30, 2026. This is the target date for the FDA to make a decision on this application.
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo is being developed by Cara Therapeutics for the treatment of its target indication. It is currently in Phase 1 clinical trials.
If Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo receives FDA approval, Cara Therapeutics (CARA) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 1 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for CARA on DilutionWatch at dilutionwatch.com/stock/CARA.html.
You can view the full BiotechSigns company profile for Cara Therapeutics (CARA) at biotechsign.com/app/company/CARA, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.